^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Viral replication inhibitor

    Related drugs:
    6d
    A Phase III Study of Deuremidevir Hydrobromide for the Treatment of RSV Infection in Infants and Young Children (clinicaltrials.gov)
    P3, N=498, Recruiting, Simcere Pharmaceutical Co., Ltd | Not yet recruiting --> Recruiting
    Enrollment open
    8d
    Phase 2a Study of the Efficacy and Safety of TRX-100 in a Human Influenza A Challenge Model (clinicaltrials.gov)
    P2, N=165, Not yet recruiting, Traws Pharma, Inc.
    New P2 trial
    10d
    ZELA: Efficacy and Safety of Zelpultide Alfa in Preterm Neonates at High Risk of Developing Bronchopulmonary Dysplasia (BPD) (clinicaltrials.gov)
    P2/3, N=241, Recruiting, Airway Therapeutics, Inc.
    New P2/3 trial
    18d
    Study of Obeldesivir as Postexposure Prophylaxis for Filovirus Diseases Virus Disease (clinicaltrials.gov)
    P2, N=0, Withdrawn, Gilead Sciences | N=400 --> 0 | Not yet recruiting --> Withdrawn
    Enrollment change • Trial withdrawal
    1m
    A Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study of TRX-100 Tablets Evaluating the Safety, Pharmacokinetics, and Food Effect of Single Ascending Doses of TRX-100 in Healthy Volunteers (ACTRN12626000272392)
    P1, N=16, Not yet recruiting, Traws Pharma, Inc
    New P1 trial
    1m
    Single Dose Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Pevifoscorvir Sodium (ALG-000184) in Participants With Renal Impairment and in Healthy Participants With Normal Renal Function (clinicaltrials.gov)
    P1, N=30, Recruiting, Aligos Therapeutics | Not yet recruiting --> Recruiting
    Enrollment open
    1m
    OPTICOV: OPtimisation of Antiviral Therapy in Immunocompromised COVID-19 Patients: a Randomized Factorial Controlled Strategy Trial (clinicaltrials.gov)
    P2, N=256, Recruiting, ANRS, Emerging Infectious Diseases | Trial completion date: May 2025 --> Jun 2027 | Trial primary completion date: Mar 2025 --> Jun 2026
    Trial completion date • Trial primary completion date
    |
    CD4 (CD4 Molecule)
    1m
    GV1001 Subcutaneous for the Treatment of Moderate to Severe Alzheimer's Disease(AD) (clinicaltrials.gov)
    P3, N=750, Not yet recruiting, Samsung Pharmaceutical Co., Ltd. | Trial completion date: Jun 2028 --> Jul 2031
    Trial completion date
    |
    LucaVax (tertomotide)
    2ms
    A Study of ABI-2280 Vaginal Insert (Previously Referred to as ABI-2280 Vaginal Tablet) in Participants With Cervical Intraepithelial Neoplasia (clinicaltrials.gov)
    P1/2, N=44, Terminated, Antiva Biosciences | N=110 --> 44 | Trial completion date: Jun 2025 --> Oct 2025 | Recruiting --> Terminated | Trial primary completion date: Jun 2025 --> Oct 2025; Study terminated early due to Antiva business decision.
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    |
    CDKN2A (Cyclin Dependent Kinase Inhibitor 2A)
    2ms
    Evaluating Clearance of High-Risk HPV and Safety After Administration of ABI-2280 Vaginal Inserts (clinicaltrials.gov)
    P1/2, N=141, Active, not recruiting, Antiva Biosciences | Recruiting --> Active, not recruiting | Trial completion date: Feb 2026 --> Jun 2026
    Enrollment closed • Trial completion date
    2ms
    ALG-000184-202: Phase 2 Study Evaluating the Efficacy and Safety of ALG-000184 Compared with Tenofovir Disoproxil Fumarate in Untreated HBeAg-Positive and HBeAg-nNegative Adult Subjects with Chronic Hepatitis B (B-SUPREME) (2025-521178-33-00)
    P1/2, N=50, Recruiting, Aligos Therapeutics Inc.
    New P1/2 trial
    2ms
    SWISS OPTICOV: OPtimisation of Antiviral Therapy in Immunocompromised COVID-19 Patients: a Randomized Factorial Controlled Strategy Trial (clinicaltrials.gov)
    P2, N=256, Recruiting, Calmy Alexandra
    New P2 trial
    |
    CD4 (CD4 Molecule)